Perspectives from the pharmaceutical industry

British Medical Journal

Volumn 327, Issue 7419, 2003, Pages 863-864

  Bonaccorso, Silvia ^a   Sturchio, Jeffrey L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ADVERTIZING; CONSUMER; DRUG INDUSTRY; DRUG USE; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTERNET; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; SHORT SURVEY; WORLD HEALTH ORGANIZATION; ARTICLE; DRUG THERAPY; FORECASTING; HUMAN RELATION; PATIENT EDUCATION;

DRUG INDUSTRY; DRUG THERAPY; FORECASTING; HUMANS; PATIENT EDUCATION; PROFESSIONAL-PATIENT RELATIONS;

EID: 0141974835     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7419.863     Document Type: Short Survey

References (6)

1. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO, 2003.
2. Coulter A, Magee H, eds. The European patient of the future. Maidenhead: Open University Press, 2003.
3. Greenfield S, Kaplan SH, Ware JE. Expanding patient involvement in care: effects on patient outcomes. Ann Intern Med 1985;102:520-8.
4. Bonaccorso SN, Sturchio JL. For and against: Direct to consumer advertising is medicalising normal human experience: against. BMJ 2002;324:910-1.
5. Calfee JE, Winston C, Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J Law Economics 2002;45:673-90.
6. European Federation of Pharmaceutical Industries and Associations. Guidelines for internet web sites available to health professionals, patients and the public in the EU. Brussels: EFPIA, 2001. (www.efpia.org/6_publ/Internetguidelines.pdf)